Hepatitis C and Human Immunodeficiency Virus Type 1 (HIV) Research Study (Gilead GS334-0123)

Duke University Medical Center is conducting a research study to evaluate the antiviral efficacy, safety, and tolerability of GS-7977 with RBV for the treatment of chronic HCV in subjects who are co-infected with HIV.

Eligibility Criteria To participate in this study, you must be an adult who meets the following criteria:

• Has hepatitis C genotype 1, 2 or 3; treatment naïve and treatment experienced;
coinfected with HIV-1

• Screening laboratory values, test, and physical exam within acceptable ranges Duration Your participation could last up to 52 weeks.

For more information, contact April Seward at 919-681-8852 or 866-704-4673.

For more information, contact Heather Kuehn at 668-1681. (REF# Copernicus Group IRB: DUK2-12-239; Duke eIRB: 38965)